PTEN and glioblastoma: In the pursuit of identifying reliable predictive biomarkers, glioblastoma patients who did not respond to anti-PD-1 therapy were analyzed and reported to be significantly enriched in PTEN mutations, especially loss-of-function mutations within the C2 domain, leading to the establishment of a immunosuppressive context and an upregulated PI3K/mTOR pathway activity as was showed in non-responders patients with PTEN mutations [111].